Delivery Order SPE2DB22D1202-SPE2DB25FUPC0

Award Date 1/7/25
Potential Completion Date 1/8/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $22,248.04, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and...
This federal contract award, valued at $25,109.09, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REMICADE 100 MG VIALS, a medical product, and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,024.80, is a delivery order for the provision of REMICADE 100 MG VIALS. The contract has an ultimate completion date of November 15, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $12,745.09, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract is for the delivery of Remicade 100 mg vials, a pharmaceutical product, with a completion date of April 18, 2024. This is a delivery order contract with a firm fixed price pricing type. The award is not associated with any set-aside...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $5,861.84 for the supply of REMICADE 100 MG VIALS. The IDC with the DLA Troop Support Medical, valued at up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,275.20 firm fixed-price delivery order is for the supply of REMICADE 100 mg vials, a specialty pharmaceutical product. The contract has an ultimate completion date of June 14, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $15,861.69, is for the delivery of REMICADE 100 MG VIALS, a specialty medication. The contract has a period of performance through March 13, 2024 and is structured as a firm fixed-price delivery order. The award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a subsidiary...
This federal contract award, valued at $1,590.16, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REMICADE 100 mg vials, a specialty medication. This is a firm fixed-price delivery order contract with a period of performance through January 7, 2025. The contract is not designated as a set-aside and represents an open competition award. AmerisourceBergen...
This federal contract award, valued at $11,245.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order (DO) under the DLA's Indefinite Delivery Contract (IDC) for medical commodities, with a firm fixed price and an ultimate completion date of January 13, 2025. The contract covers the procurement of REMICADE 100 MG VIALS, a specialty pharmaceutical product, to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $21,941.78 delivery order contract is for the provision of Remicade 100 mg vials, a specialty medication. The contract has a firm fixed price pricing type and an ultimate completion date of December 30, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB25FUPC0
    Delivery Order

This federal contract award, valued at $11,384.38, was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the provision of REMICADE 100 MG VIALS. This contract is not associated with any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 5/21/25, 10:19 AM